Clinical Trial Update: Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II trial comparing SHR-1210 (camrelizumab) plus apatinib vs pemetrexed plus carboplatin in KRAS-mutant stage IV non-squamous non-small cell lung cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)
• SHR-1210 (camrelizumab) (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: NSCLC Stage IV, KRAS Gene Mutation | Phase 2 | Status: TERMINATED